European Commission grants marketing authorisation for subcutaneous formulation of infliximab (Remsima SC) for additional five indications

European Commission has granted marketing authorisation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis, at a 120 mg fixed dose.

Source:

Biospace Inc.